This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Omron Launches Sleep Monitor With ResMed Technology

SAN DIEGO, May 23, 2012 /PRNewswire/ -- ResMed Inc. (NYSE:RMD) today announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device. The Omron Sleep Design HSL-101 is part of a new strategy by Omron, named "All for Healthcare."

(Photo: http://photos.prnewswire.com/prnh/20120523/LA12821)

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

How Omron Sleep Design Works

The device uses ResMed technology to offer wireless, non-contact sleep monitoring which in turn connects to health care support services in Japan. To use the Omron Sleep Design HSL-101, a patient places the device beside the bed. With ResMed's non-contact sensing technology, the device measures sleep throughout the night and can report key sleep quality metrics, such as sleep onset time and total sleep time. In the morning, users can generate a full report on the night's sleep with the push of a button. When the data is connected to the cloud as part of Omron's Wellness Link service, a full picture of sleep health is provided, alongside a customized summary of health tips and advice.

ResMed and BiancaMed

ResMed is a leading developer, manufacturer and distributor of systems to diagnose, treat and manage sleep-disordered breathing, a serious health condition in which people experience breathing issues during sleep ranging from simple snoring to periods of completely obstructed breathing, known as sleep apnea. As such, ResMed recognizes that sleep monitoring represents a huge market opportunity globally, part of an increasing recognition of the impact of disturbed sleep on numerous important health issues, including heart disease, stroke, type 2 diabetes and more, as well as an increasing trend toward proactive, preventative health care models.

The need for convenient, cost-effective screening and monitoring solutions continues to grow as economic pressures are causing governments and insurance providers worldwide to focus on cost savings and therapeutic efficacy in both the diagnosis and treatment of health disorders. ResMed's acquisition of BiancaMed in 2011 serves this need two-fold: by providing a simple screening solution, and by providing novel alternatives for monitoring across multiple disease categories, such as heart failure, diabetes and more.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs